Here are a few brief analogies for UroGen Pharma:

• UroGen Pharma is like Vertex Pharmaceuticals, but instead of focusing on cystic fibrosis, it specializes in developing novel treatments for urothelial cancers and diseases.
• UroGen Pharma is like a specialized version of Moderna, developing novel treatments for specialty cancers and urothelial diseases using its unique RTGel drug delivery platform, rather than mRNA.

• RTGel: A polymeric hydrogel technology designed to improve drug delivery and therapeutic profiles of existing drugs.
• Jelmyto: A pyelocalyceal solution offered for the treatment of low-grade upper tract urothelial carcinoma.
• UGN-102: A lead product candidate in Phase III clinical trials for various forms of low-grade non-muscle invasive urothelial cancer.
• UGN-301: A product candidate under development for the treatment of high-grade non-muscle invasive bladder cancer.

UroGen Pharma (URGN) primarily sells its products, technologies, and services to other companies and institutions within the healthcare and pharmaceutical sectors. Based on the provided background information, its major customers include:

• AbbVie Inc. (symbol: ABBV): UroGen Pharma has a license agreement with Allergan Pharmaceuticals International Limited, a subsidiary of AbbVie, for the development and commercialization of pharmaceutical products containing RTGel and clostridial toxins. This indicates AbbVie, through Allergan, is a customer for UroGen's RTGel technology.
• Agenus Inc. (symbol: AGEN): UroGen Pharma has an agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize Agenus products for the treatment of cancers of the urinary tract via intravesical delivery. This suggests Agenus is a customer for UroGen's development and commercialization expertise and services.

Additionally, for its commercialized product Jelmyto and future approved therapies, UroGen Pharma's direct customers would be healthcare providers and institutions such as hospitals, clinics, and specialty pharmacies, as well as pharmaceutical distributors and wholesalers. However, specific names for these types of customers are not provided in the background description.

• Patheon UK Limited (subsidiary of Thermo Fisher Scientific, TMO)
• Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872)

Liz Barrett, President and Chief Executive Officer

Liz Barrett was appointed President and Chief Executive Officer of UroGen Pharma in January 2019. She has over 30 years of experience in oncology and pharmaceutical development. Prior to joining UroGen, Ms. Barrett served as CEO of Novartis Oncology and was a member of the Novartis Executive Committee. She also held numerous leadership positions at Pfizer Inc., including Global President of Oncology, President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Earlier in her career, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc., where she built the oncology business from scratch, and also held positions at Johnson & Johnson and Kraft Food Groups, Inc.

Chris Degnan, Chief Financial Officer

Chris Degnan was appointed Chief Financial Officer of UroGen Pharma in October 2024. He has extensive experience as a CFO in publicly traded biotech companies, having previously served as CFO at Galera Therapeutics, Inc. from October 2019 to August 2024, and at Verrica Pharmaceuticals from March 2018 to October 2019. Mr. Degnan's background also includes senior finance leadership roles at Endo Pharmaceuticals from November 2014 to March 2018, and over a decade at AstraZeneca from May 2004 to November 2014. He began his career as a Senior Accountant at KPMG LLP.

Mark P. Schoenberg, M.D., Chief Medical Officer

Dr. Mark P. Schoenberg has served as UroGen Pharma's Chief Medical Officer since December 2017, having previously been the company's Medical Director since February 2016. He is an internationally recognized expert in the treatment of urothelial cancer and has over 20 years of experience in clinical practice and research in the field. Dr. Schoenberg held prominent academic positions, including Director of Urologic Oncology and Bernard Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins University from 2005 to 2014. He is currently a University Professor and Chair of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Dr. Schoenberg completed his urologic oncology fellowship at The James Buchanan Brady Urological Institute of Johns Hopkins University and is a founding member of the scientific advisory board of The Bladder Cancer Advocacy Network.

Marina Konorty, Ph.D., Executive Vice President, Research & Development

Marina Konorty holds the position of Executive Vice President, Research & Development at UroGen Pharma.

David Lin, Chief Commercial Officer

David Lin serves as the Chief Commercial Officer at UroGen Pharma.

The key risks to UroGen Pharma (URGN) primarily revolve around the successful development and commercialization of its pipeline products, its financial stability, and external market factors such as competition and supply chain vulnerabilities.

1. Regulatory and Commercialization Risk of Pipeline Products

UroGen Pharma's future success is heavily dependent on obtaining regulatory approvals and achieving significant market adoption for its product candidates, especially UGN-102. Although UGN-102, an intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), has received FDA approval, its path was marked by regulatory challenges. The FDA's Oncologic Drugs Advisory Committee (ODAC) previously voted against a favorable benefit-risk profile for UGN-102, citing concerns about the study design, particularly the lack of a concurrent control arm in the ENVISION clinical study. This raised questions about whether the observed duration of response was solely attributable to the drug or the natural course of the disease. Even with approval, the commercial uptake of UGN-102 remains uncertain, as physician adoption of a new, non-surgical treatment must overcome entrenched surgical standards for LG-IR-NMIBC. Any delays, failures, or limited market acceptance of pipeline products can significantly impact the company's revenues and overall growth.

2. Financial Health and Funding Risks

UroGen Pharma exhibits a poor financial strength rating, characterized by high debt levels and a concerning debt-to-equity ratio, indicating potential financial instability. The company has reported significant operating losses and negative net margins, with its Altman Z-Score placing it in the distress zone, which suggests a potential risk of bankruptcy. As a biotechnology company, UroGen Pharma faces substantial development costs and a constant need for capital, relying on a limited cash runway. This financial position increases the likelihood of needing future capital raises, which could dilute existing shareholders, or requiring non-dilutive financing to support its research, development, and commercialization efforts.

3. Supply Chain Vulnerabilities, Trade Tensions, and Competition

UroGen Pharma's reliance on a global supply chain and specialized third-party manufacturers exposes it to risks from shifting tariffs, sanctions, and other trade barriers. These factors can lead to increased input and manufacturing costs, potentially eroding profit margins, particularly as reimbursement frameworks for its products may limit the company's ability to pass on these cost increases to payers. Furthermore, the lack of in-house production capabilities restricts its flexibility to adapt to supply chain disruptions. The biotechnology sector is highly competitive, with numerous companies vying for market share. UroGen Pharma's proprietary RTGel® technology and its products face increasing competition from new treatment modalities, including gene therapies, immunotherapies, and antibody-drug conjugates being developed by competitors for urothelial cancers, a market UroGen aims to penetrate. Unlike larger pharmaceutical companies, UroGen lacks a diversified portfolio of revenue-generating products, making it more vulnerable to competitive pressures and the success or failure of its limited product offerings.

• Jelmyto (for low-grade upper tract urothelial carcinoma): null
• UGN-102 (for low-grade intermediate-risk non-muscle invasive bladder cancer): The estimated market opportunity is over $5 billion in the U.S.
• UGN-301 (for high-grade non-muscle invasive bladder cancer): The Non-Muscle Invasive Bladder Cancer (NMIBC) therapeutics market size in the 7MM (US, EU4, UK, and Japan) for high-risk NMIBC was approximately $1.6 billion in 2023.

UroGen Pharma (URGN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives related to its commercialized products and advancing pipeline:

1. Continued Growth in Jelmyto Sales: Jelmyto (mitomycin) for pyelocalyceal solution, currently a stable revenue source for UroGen, is projected to see continued growth. The company forecasts net product sales for Jelmyto to reach between $97 million and $101 million in 2026, representing an anticipated growth rate ranging from 3% to 7% compared to 2025 sales of $94 million.
2. Commercial Launch and Expanding Market Penetration of ZUSDURI (UGN-102): The FDA approval and subsequent commercial launch of ZUSDURI (formerly UGN-102) in June 2025 for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a transformative milestone for UroGen. This product targets a significant market opportunity estimated to be over $5 billion. The implementation of a permanent, product-specific J-code for ZUSDURI on January 1, 2026, is expected to accelerate adoption by simplifying reimbursement and improving patient access, thereby driving substantial revenue growth in 2026 and beyond. Analysts anticipate ZUSDURI to generate $118 million in revenue in 2026 and $224 million by 2027.
3. Potential Approval and Launch of UGN-103: UroGen is advancing UGN-103, another mitomycin-based RTGel formulation, with an NDA submission planned for the second half of 2026. Positive clinical trial results, demonstrating a 77.8% complete response at three months in the Utopia Phase 3 trial, position UGN-103 as a significant potential new product contributing to future revenue streams if approved.
4. Advancement of the Broader Pipeline: Beyond its lead products, UroGen is actively progressing other pipeline candidates, including UGN-301 for high-grade non-muscle invasive bladder cancer and UGN-104. The company aims to complete Phase 3 enrollment for UGN-104 by the end of 2026, which could further broaden its product portfolio and contribute to long-term revenue growth.

Share Issuance

• In July 2023, UroGen Pharma completed a private placement, issuing 7,300,380 ordinary shares and 5,278,776 pre-funded warrants, which resulted in aggregate gross proceeds of $120.0 million.
• The number of ordinary shares outstanding increased from 22.43 million in 2021 to 48.05 million by the end of 2025.
• As of February 24, 2026, UroGen Pharma had 48,682,280 ordinary shares outstanding.

Inbound Investments

• The company raised $120.0 million in aggregate gross proceeds from a private placement of ordinary shares and pre-funded warrants in July and August 2023.
• UroGen refinanced its term loan with Pharmakon Advisors, securing a new $250 million loan agreement. This included an initial tranche of $200 million and an optional second tranche of $50 million, providing additional non-dilutive capital.

Capital Expenditures

• Capital expenditures were reported as $1.215 million in 2021.
• Capital expenditures were $0.295 million in 2024.
• Forecasted capital expenditures are $4 million for 2025 and $6 million for 2026.